Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

242
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
242
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

16
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
16
iPS Cell Differentiation01:22

iPS Cell Differentiation

2.8K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.8K
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

18
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
18
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

169
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
169
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efgartigimod as a treatment for adults with primary immune thrombocytopenia: a plain language summary of the ADVANCE IV study.

Therapeutic advances in hematology·2026
Same author

Efficacy and Safety of Subcutaneous Efgartigimod PH20 in Adults With Primary Immune Thrombocytopenia (ADVANCE SC): A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 3 Trial.

American journal of hematology·2026
Same author

Introduction to the Review Series. A century after Erik von Willebrand.

Haematologica·2026
Same author

Splenectomy: still a life-saving treatment in immune thrombocytopenia.

Haematologica·2025
Same author

Use of second-line and beyond maintenance therapies in adult patients with primary immune thrombocytopenia in Europe: a parallel study of six prospective multicenter national registries.

Haematologica·2025
Same author

Mild or moderate hemophilia is not always a mild or moderate bleeding disorder: Back to the clinical phenotype.

HemaSphere·2025

Related Experiment Video

Updated: Aug 14, 2025

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
09:52

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

13.5K

Recent progress in ITP treatment.

Francesco Rodeghiero1

  • 1Hematology Project Foundation, Affiliated to the Department of Hematology, "S. Bortolo" Hospital, ContrĂ  San Francesco 41, 36100, Vicenza, Italy. rodeghiero@hemato.ven.it.

International Journal of Hematology
|January 9, 2023
PubMed
Summary

Newer therapies for immune thrombocytopenia (ITP), including avatrombopag and fostamatinib, offer alternatives to existing treatments. While promising, careful consideration of side effects and quality of life is essential for optimal patient management.

Keywords:
AvatrombopagFostamatinibITPNew agents

More Related Videos

Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity
09:38

Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity

Published on: January 31, 2025

532
Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

12.0K

Related Experiment Videos

Last Updated: Aug 14, 2025

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
09:52

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

13.5K
Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity
09:38

Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity

Published on: January 31, 2025

532
Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

12.0K

Area of Science:

  • Hematology
  • Pharmacology
  • Immunology

Background:

  • Immune thrombocytopenia (ITP) management guidelines have evolved since 2019.
  • Recent advancements include novel oral and targeted therapies for ITP.

Purpose of the Study:

  • To review recently approved drugs for ITP not extensively covered in prior recommendations.
  • To discuss the efficacy, safety, and administration of avatrombopag and fostamatinib.
  • To explore emerging treatment combinations and novel agents in clinical development.

Main Methods:

  • Review of recently approved drugs (avatrombopag, fostamatinib) and their clinical data.
  • Analysis of clinical trial data for new treatment combinations and targeted agents.
  • Discussion of agents targeting specific immune mechanisms (complement, BTK, FcRn).

Main Results:

  • Avatrombopag offers a convenient oral option for ITP, but QoL data and thromboembolic event rates require monitoring.
  • Fostamatinib demonstrates efficacy in refractory ITP with a manageable safety profile, including hypertension and diarrhea.
  • Newer agents like sutimlimab, rilzabrutinib, and efgartigimod are under investigation, with efgartigimod completing Phase 3.

Conclusions:

  • Avatrombopag and fostamatinib represent important additions to the ITP treatment landscape.
  • Ongoing research into novel combinations and targeted therapies holds promise for improved ITP management.
  • Further data on quality of life and long-term safety are needed for newer ITP therapies.